Abstract
To the Editor: MEK (small-molecule mitogen-activated protein kinase [MAPK]/extracellular signal-regulated kinase [ERK]) is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell proliferation and survival; constitutive activation of this pathway is implicated in many solid tumors.1 The benzimidazole AZD6244 (ARRY-142886) is an orally available, highly selective MEK inhibitor that is being evaluated in early clinical trials.2,3 We report the cutaneous side effects of AZD6244 in a patient with metastatic papillary thyroid cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
